Combination of calcipotriol and betamethasone in psoriasis treatment

November 2014
Klinicheskaya Dermatologia I Venerologia;2014, Issue 6, p54
Academic Journal
Fixed-dose combination of vitamin D3 analog and glucocorticosteroid betamethasone (calcipotriol 50 mg/kg and betamethasone 0.5 mg/kg) is recommended for daily use in patients with different clinical forms of psoriasis. The main mechanisms of action include proliferation suppression and normalization of keratinocyte differentiation, as well as immunomodulating, antiinflammatory, and peeling effects, which rapidly eliminate the major signs of dermatosis. Material and methods. The effectiveness of the combination drug (calcipotriol + betamethasone) in the form of gel and ointment was assessed in 118 patients with different clinical forms of psoriasis. Results. The combination therapy proved to be effective when daily used by patients with psoriasis for up to 8 weeks, as well as when used for up to 52 weeks. Conclusions. The convenient dosage scheme (once daily), high effectiveness, several dosage forms, minimal adverse effects, positive effect on quality of life, and pharmaco-economic benefit make this pharmaceutical the first-line drug in treatment of psoriasis with different location.


Related Articles

  • Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Patel, Nupur U.; Felix, Kayla; Reimer, Danielle; Feldman, Steven R. // Clinical, Cosmetic & Investigational Dermatology;Sep2017, Vol. 10, p385 

    While topical medications remain the cornerstone of the psoriasis treatment paradigm, they also come with the risk of multiple side effects. An alternative topical treatment option, calcipotriene or calcipotriol, is a vitamin D derivative that is thought to work by inhibiting keratinocyte...

  • Treatment Options For Psoriasis Expanding. Guttman, Cheryl // Dermatology Times;May99, Vol. 20 Issue 5, p3 

    Identifies emerging therapies for the treatment of psoriasis in the United States. Narrow-band ultraviolet; Mycophenolate mofetil; 6-thioguanine; Corticosteroid foams for scalp use; Biotechnology agents for blocking T-cell activation.

  • Psoriasis: A short course in topical agents. Greenberg, Robert G. // Cortlandt Forum;May2008, Vol. 21 Issue 5, p23 

    The article presents a treatment option for psoriasis, a chronic skin disease characterized by dry red patches covered with scales. It states that topical corticosteroids are the most common form of treatment for this disease. It advises that the strength, vehicle formulation and quantity...

  • Classical to Current Approach for Treatment of Psoriasis: A Review. Rahman, Mahfoozur; Alam, Kainat; Zaki Ahmad, Mohammad; Gupta, Gaurav; Afzal, Muhammad; Akhter, Sohail; Kazmi, Imran; Jyoti; Jalees Ahmad, Farhan; Anwar, Firoz // Endocrine, Metabolic & Immune Disorders - Drug Targets;Sep2012, Vol. 12 Issue 3, p287 

    Psoriasis is a genetic predisposition with T-cell mediated autoimmune inflammatory skin disorder, characterized by cutaneous inflammation, increased epidermal proliferation, hyperkeratosis, angiogenesis, and abnormal keratinization that affects up to 2 - 3% of the population worldwide. Common...

  • BJD Editor's Choice.  // Journal of Investigative Dermatology;Oct2012, Vol. 132 Issue 10, p2310 

    The article offers information related to the treatment of several skin disorders. It informs that etanercept plus methotrexate can be a viable regimen in the patients suffering from psoriasis. It further states that using oral tofacitinib for treating psoriasis results a significant clinical...

  • Comparative safety of topical calcipotriol (0.005%) versus topical corticosteroid (betamethasone 0.1%) in plaque type psoriasis. Gulam Kazem Ali Ahmad; Choudhury, A. M.; Khondker, Lubna; Khan, M. S. I. // Journal of Pakistan Association of Dermatologists;Oct-Dec2013, Vol. 23 Issue 4, p394 

    Objective To compare the safety of topical calcipotriol (0.005%) and topical corticosteroid (betamethasone 0.1%) in the treatment of plaque type psoriasis. Patients and methods A clinical trial was carried out from January 2012 to August 2012 and patients of plaque type psoriasis attending...

  • Therapeutics.  // Current Medical Literature: Dermatology;2009, Vol. 14 Issue 3, p62 

    The article presents updates on the treatment of skin diseases. An updated guideline for the use of methotrexate in the treatment of psoriasis was released by the Medical Board of National Psoriasis Foundation. Systemic corticosteroids were considered as mainstays for the treatment of chronic...

  • Addition of a Topical Corticosteroid in the Early Phase of Alefacept Treatment for Psoriasis. Bovenschen, H. Jorn; Gerritsen, Wil-Janne; de Jong, Elke M. G. J.; van de Kerkhof, Peter C. M. // Acta Dermato-Venereologica;May2006, Vol. 86 Issue 3, p281 

    The article presents a case study which looks into the effectiveness and efficacy of corticosteroid-alefacept combination treatment for psoriasis in 16 patients. The study has found out a time-related improvement in Psoriasis Area and Severity Index (PASI) despite the failure of the treatment...

  • Corticosteroid sensitive to complications.  // Dermatology Times;Nov99 Supplement 6, Vol. 20 Issue 11, pS34 

    Reports on the effectiveness of the corticosteroid fluticasone propionate in treating adults with psoriasis and atopic dermatitis of the face and intertriginous areas. Potential side effects; Efficacy of limited application; Marketing clearance of the United States Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics